With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

For this review, the authors searched for randomized controlled trials published in MEDLINE, Embase, and Cochrane CENTRAL ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

Research showed that patients who lose weight on GLP-1 agonists frequently experience muscle mass loss. Obesity experts share ...

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

Expanding volumes of data point to mechanisms beyond weight loss and blood sugar control that contribute to cardiovascular ...

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

Results showed patients with a BMI of 40 kg/m2 or more who used glucagon-like peptide-1 receptor agonists for at least 90 ...

The firm said it struck a three-year licensing deal with a top pharmaceutical company that will use the data to advance GLP-1 receptor agonist research.

John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors.